25780 (EXAC)
| Previous Close | N/A |
| YTD Return | N/A |
| Expense Ratio (net) | N/A |
| Category | N/A |
| Last Cap Gain | N/A |
| Morningstar Rating | N/A |
| Morningstar Risk Rating | N/A |
| Sustainability Rating | N/A |
| Net Assets | N/A |
| Beta (5Y Monthly) | N/A |
| Yield | N/A |
| 5y Average Return | N/A |
| Holdings Turnover | N/A |
| Last Dividend | N/A |
| Average for Category | N/A |
| Inception Date | N/A |
- Moody's
Exactech, Inc. -- Moody's announces completion of a periodic review of ratings of Exactech, Inc.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Exactech, Inc. New York, May 21, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Exactech, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- Moody's
Exactech, Inc. -- Moody's downgrades Exactech's CFR to B3, outlook negative
Moody's Investors Service ("Moody's") today downgraded Exactech Inc.'s Corporate Family Rating to B3 from B2 and its Probability of Default Rating to B3-PD from B2-PD. Moody's also downgraded the company's first lien credit facility ratings to B3 from B2. The rating actions reflect Moody's expectations that guidance from various public health authorities and physician associations is likely to lead to a meaningful decline in elective procedures as treating COVID-19 patients will be a priority.
